We have previously shown that a patient-derived tumour xenograft with FGFR1 amplification but low level FGFR1 protein expression was less sensitive to AZD4547 treatment than models with co-occuring FGFR1 amplification and high FGFR1 protein expression [10]. The gene discussed is FGFR1; the disease is neoplasm.